Your browser doesn't support javascript.
loading
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Calsina, Bruna; Piñeiro-Yáñez, Elena; Martínez-Montes, Ángel M; Caleiras, Eduardo; Fernández-Sanromán, Ángel; Monteagudo, María; Torres-Pérez, Rafael; Fustero-Torre, Coral; Pulgarín-Alfaro, Marta; Gil, Eduardo; Letón, Rocío; Jiménez, Scherezade; García-Martín, Santiago; Martin, Maria Carmen; Roldán-Romero, Juan María; Lanillos, Javier; Mellid, Sara; Santos, María; Díaz-Talavera, Alberto; Rubio, Ángeles; González, Patricia; Hernando, Barbara; Bechmann, Nicole; Dona, Margo; Calatayud, María; Guadalix, Sonsoles; Álvarez-Escolá, Cristina; Regojo, Rita M; Aller, Javier; Del Olmo-Garcia, Maria Isabel; López-Fernández, Adrià; Fliedner, Stephanie M J; Rapizzi, Elena; Fassnacht, Martin; Beuschlein, Felix; Quinkler, Marcus; Toledo, Rodrigo A; Mannelli, Massimo; Timmers, Henri J; Eisenhofer, Graeme; Rodríguez-Perales, Sandra; Domínguez, Orlando; Macintyre, Geoffrey; Currás-Freixes, Maria; Rodríguez-Antona, Cristina; Cascón, Alberto; Leandro-García, Luis J; Montero-Conde, Cristina; Roncador, Giovanna; García-García, Juan Fernando.
Affiliation
  • Calsina B; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. bcalsina@cnio.es.
  • Piñeiro-Yáñez E; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Martínez-Montes ÁM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Caleiras E; Histopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Fernández-Sanromán Á; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Monteagudo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Torres-Pérez R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Fustero-Torre C; Bioinformatics for Genomics and Proteomics, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain.
  • Pulgarín-Alfaro M; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Gil E; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Letón R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Jiménez S; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • García-Martín S; Monoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Martin MC; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Roldán-Romero JM; Molecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Lanillos J; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Mellid S; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Santos M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Díaz-Talavera A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Rubio Á; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • González P; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Hernando B; Genomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Bechmann N; Histopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Dona M; Computational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Calatayud M; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Guadalix S; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Álvarez-Escolá C; Department of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain.
  • Regojo RM; Department of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain.
  • Aller J; Department of Endocrinology, La Paz University Hospital, Madrid, Spain.
  • Del Olmo-Garcia MI; Department of Pathology, La Paz University Hospital, Madrid, Spain.
  • López-Fernández A; Department of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain.
  • Fliedner SMJ; Department of Endocrinology and Nutrition, University Hospital La Fe, Valencia, Spain.
  • Rapizzi E; Department of Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain.
  • Fassnacht M; Neuroendocrine Oncology and Metabolism, Medical Department I, Center of Brain, Behavior, and Metabolism, University Medical Center Schleswig-Holstein Lübeck, Lübeck, Germany.
  • Beuschlein F; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
  • Quinkler M; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany.
  • Toledo RA; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
  • Mannelli M; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
  • Timmers HJ; Klinik für Endokrinologie Diabetologie und Klinische Ernährung, Universitätsspital Zürich (USZ) und Universität Zürich (UZH), Zürich, Switzerland.
  • Eisenhofer G; Endocrinology in Charlottenburg Stuttgarter Platz 1, Berlin, Germany.
  • Rodríguez-Perales S; Gastrointestinal and Endocrine Tumors, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Domínguez O; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Macintyre G; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
  • Currás-Freixes M; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Rodríguez-Antona C; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Cascón A; Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Leandro-García LJ; Molecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Montero-Conde C; Genomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Roncador G; Computational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • García-García JF; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Nat Commun ; 14(1): 1122, 2023 02 28.
Article de En | MEDLINE | ID: mdl-36854674
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Paragangliome / Phéochromocytome / Seconde tumeur primitive / Tumeurs de la surrénale Limites: Humans Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2023 Type de document: Article Pays d'affiliation: Espagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Paragangliome / Phéochromocytome / Seconde tumeur primitive / Tumeurs de la surrénale Limites: Humans Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2023 Type de document: Article Pays d'affiliation: Espagne